In order to describe the prevalence of hypercholesterolemia and hypertriglyceridemia in a cohort of HIV-infected children and adolescents in Latin America and to determine associations with highly active antiretroviral therapy (HAART), we performed this cross-sectional analysis within the NICHD International Site Development Initiative pediatric cohort study. Eligible children had to be at least 2 years of age and be on HAART. Among the 477 eligible HIV-infected youth, 98 (20.5%) had hypercholesterolemia and 140 (29.4%) had hypertriglyceridemia. In multivariable analyses, children receiving protease inhibitor (PI)-containing HAART were at increased risk for hypercholesterolemia [adjusted odds ratio (AOR) ¼ 2.7, 95% confidence interval (CI) 1.3-5.6] and hypertriglyceridemia (AOR ¼ 3.5, 95% CI 1.9-6.4) compared with children receiving non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing HAART. In conclusion, HIV-infected youth receiving PI-containing HAART in this Latin American cohort were at increased risk for hypercholesterolemia and hypertriglyceridemia compared with those receiving NNRTIcontaining HAART.
Introduction
In the USA and Europe great success has been achieved in initiating, maintaining and monitoring HIV positive children and adolescents on antiretroviral therapy (ART), however; concerns about a range of adverse drug effects have also emerged. Numerous studies have found ART to be associated with various metabolic complications [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Hyperlipidemia is particularly concerning in the pediatric context as children must be on ART for extended, even life-long, periods of time, resulting in long-term exposure to the potentially harmful cardiovascular consequences of elevated lipid levels. In resource-constrained countries, limited access to ART is still a major obstacle. In 2008, worldwide, only 38% of HIV-infected children in need of ART living in low-and middle-income countries were receiving it [11] . However, improved access to ART has increased the estimated total number of children receiving ART from about 75 000 in 2005, to 198 000 in 2007 and 275 700 in 2008 [11, 12] . New World Health Organization recommendations that all HIV infected infants and children 2 years of age start life-long ART, regardless of clinical or immunologic stage, and earlier initiation criteria for those !2 years of age will lead to further dramatic increases in the number of infants and children receiving treatment around the world [13, 14] . As this progress is made and more children begin to receive life-saving ART, understanding the adverse drug effects associated with exposure to ART will become increasingly important for clinicians and public-health officials worldwide. Studies of treated HIV-infected children and adolescents in resource-constrained settings are needed in order to document the frequency of metabolic complications among pediatric cohorts in these settings where environmental and other factors that impact on these complications (e.g. diet, co-morbid conditions, race and ethnicity) differ from those in resource-rich settings.
In Latin America, especially in Brazil, pediatric access to ART has been better than the global average. According to the 2009 UNAIDS Universal Access Report, as of December 2008, 76% of the HIV positive children in Latin America and the Caribbean in need of ART were receiving it [11] . The objectives of the present analysis were to describe the prevalence of hypercholesterolemia and hypertriglyceridemia in a cohort of Latin American HIV-infected children and to determine the associations between highly active ART (HAART) and hyperlipidemia, using data collected as part of an ongoing observational cohort study being conducted at multiple Latin American sites [15] . A description of this protocol and the cohort has been published [15] . The NICHD Institutional Review Board (IRB), the data management and statistical center IRB, separate in-country ethics committees and national review boards (where required, i.e., Brazil) reviewed and approved the protocol. Informed consent was obtained from either parents or guardians or from subjects who were able to provide consent based upon local laws. Assent was obtained from subjects >8 years of age when developmentally appropriate.
Materials and Methods

NISDI pediatric cohort
An objective of the NISDI pediatric protocol is to describe early and late outcomes related to HIV disease and ART in HIV-infected infants, children and adolescents. To this end, the following were performed at 6-month intervals: medical history, physical examination, hematology, flow cytometry and standard biochemical assays including total cholesterol and triglycerides. The protocol did not require samples for cholesterol and triglycerides to be collected in the fasting state, but it was the practice at most of the sites to perform these tests when subjects were fasting. Cholesterol and triglycerides were measured by routine methods at each site's local laboratory. The 2000 CDC growth charts were used to characterize growth parameters [16] . HIV disease was classified according to the CDC Classification System [17] .
Study population
To be eligible for this cross-sectional analysis, HIV-infected children in the NISDI pediatric cohort had to be at least 2 years of age at the time of their enrollment study visit or at the time of the first on study cholesterol and triglyceride testing and be on HAART, defined below, on the day the laboratory tests were performed. We excluded children who were not on ART or who were on single or dual ART because selection of therapy was not randomized and thus these groups likely differed from those on HAART in substantial ways. Children with diabetes, nephrotic or nephritic syndrome, uremia or hypothyroidism were also excluded. . Subjects were considered to be on HAART if they were taking at least three antiretrovirals that included at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI). Subjects were considered to be on: (i) NNRTI-containing HAART if they were receiving an NNRTI along with nucleoside reverse transcriptase inhibitors (NRTIs); (ii) PI-containing HAART if they were receiving at least one PI along with NRTIs; and (iii) PI þ NNRTI-containing HAART if they were on a regimen containing at least one PI, an NNRTI and at least one NRTI.
Statistical analysis
The outcomes of interest were hypercholesterolemia and hypertriglyceridemia. Chi-square analysis was used to identify categorical variables associated with the two outcomes, respectively. Variables associated with the outcomes in the bivariate models (at the 20% significance level, p 0.2) were included in the multivariable logistic regression models. We used stepwise selection and backward elimination methods to determine the most parsimonious model. Only variables with a p-value <0.05 remained in the final model. Statistical analyses were performed using SAS 9.1 software (SAS Institute Inc., Cary, NC, USA).
Results
As of October 2007, there were 816 HIV-infected subjects enrolled in the NISDI pediatric cohort. The derivation of the study population for this analysis is shown in Fig. 1 . Subjects <2 years of age and all of those with nephrotic syndrome, uremia, and hypothyroidism were excluded from the study. Subjects who were not on ART (n ¼ 109) or who were on single or dual ART (n ¼ 122) at the time of cholesterol and triglyceride testing were excluded.
Among the 109 subjects not on ART, only 7 (6.4%) had hypercholesterolemia and 12 (11.0%) had hypertriglyceridemia; among the 122 subjects on single or dual ART only one (0.8%) had hypercholesterolemia and 19 (15.6%) had hypertriglyceridemia. The final study population used in this analysis consisted of 477 subjects on HAART.
Characteristics of this study population according to the regimens they were receiving at the time of cholesterol testing are shown in Table 1 . Median age overall was 6.8 years (range 2-20.5 years). Most of the 477 children were vertically infected (90.4%) and most had been on their current HAART regimen for at least 6 months (82.9%) at the time of cholesterol and triglyceride testing. The cohort consists of children from Argentina, Mexico, Jamaica, Peru and Brazil with the latter contributing the greatest proportion of children (61.4%). Subjects on NNRTI-containing HAART did not differ significantly from those on PI-containing HAART with respect to the percent who had received a previous HAART regimen or duration of previous HAART, but were significantly more likely to have less severe HIV disease (p < 0.001). A majority of those receiving a PI (58.3%) were on nelfinavir, followed by ritonavir (31.1%).
Overall (IQR 150-204) for the PI þ NNRTI-containing HAART group (Fig. 2a) . Median triglyceride levels were 74.5 mg dl À1 (IQR 55-104) for the NNRTI-containing HAART group, 117.0 mg dl À1 (IQR 88-171) for the PI-containing HAART group, and 114.5 mg dl À1 (IQR 91-165) for the PI þ NNRTI-containing HAART group (Fig. 2b) .
All categorical variables shown in Table 1 were evaluated for their association with hypercholesterolemia and hypertriglyceridemia in bivariate analysis. Race and ethnicity, however, were not considered in the multivariable models due to insufficient data. Although country of residence was associated with hypercholesterolemia and hypertriglyceridemia at the bivariate level (<0.0001 and 0.02, respectively), this variable was not included in the final multivariable models due to insufficient numbers of eligible clients from Jamaica (n ¼ 13) and Peru (n ¼ 16). Although not shown in Table 1 , we also evaluated the association between age at the time of initiating first HAART regimen and hypercholesterolemia and hypertriglyceridemia.
Factors associated with hypercholesterolemia
In bivariate analysis, PI-containing HAART regimen (p < 0.01), high CD4 percent (p < 0.01), low viral load (p < 0.0001), country of residence (p < 0.0001), age at the time of lab test (0.11), and duration of time on HAART !6 months (p ¼ 0.18) were associated with high cholesterol at the 20% significance level. These variables, with the exception of country, were considered for multivariable modeling (Table 2) , and HAART regimen, CD4 percent, and viral load remained in the final model. Children on PI-containing HAART as well as those on PI þ NNRTI-containing HAART were at increased risk for high cholesterol compared to children on NNRTI-containing HAART [adjusted odds ratio (AOR) ¼ 2.7, 95% confidence interval (CI) 1.3-5.6 and AOR ¼ 2.7, 95% CI 1.1-7.0, respectively]. Hypercholesterolemia was also inversely associated with viral load. Children with a detectable viral load were less likely than children with undetectable levels to have high cholesterol (AOR ¼ 0.3, 95% CI 0.2-0.6) and those with a CD4 percent <15 were less likely than those with a CD4 percent >25 to have hypercholesterolemia (AOR ¼ 0.3, 95% CI 0.1-0.9)
Factors associated with hypertriglyceridemia
In bivariate analysis, PI-containing HAART regimen (p < 0.001), low body mass index (BMI) (p ¼ 0.10), country of residence (p ¼ 0.02), having received a previous HAART regimen (p ¼ 0.02), age at the time of lab test (p ¼ 0.16), and age at the time of initiating the current HAART regimen (0.03), met the criteria to enter the multivariable hypertriglyceridemia model (Table 3) . Only HAART regimen, BMI, age at the time of initiating the current HAART regimen, and having received a previous HAART regimen remained in the final model (Table 3 ). While the association between age at the time of initiating the first HAART regimen and hypertriglyceridemia met the criteria for inclusion into the multivariable model (p ¼ 0.8), we did not include it due its significant correlation with age at the time of initiating current HAART regimen (r ¼ 0.94). Children on PI-containing HAART were 3.5 times more likely to have high triglycerides than children on NNRTI-containing HAART (AOR ¼ 3.5, 95% CI 1.9-6.4). BMI was also a significant factor with underweight children being at higher risk of high triglycerides than children with a normal BMI (AOR ¼ 2.1, 95% CI 1.1-4.2).
Discussion
To our knowledge, the study population presented here is the largest described to date for a Latin American pediatric HIV cohort and demonstrates high rates of hypercholesterolemia and hypertriglyceridemia in HIV-infected children and adolescents. As compared with children on NNRTI-containing HAART, we found that children on PI-containing HAART were approximately three times more likely to have hypercholesterolemia and hypertriglyceridemia, independent of other risk factors. Similar associations between hyperlipidemia and PI-containing HAART have been reported previously in HIV infected pediatric populations, primarily in Europe and the USA [1-3, 5, 7-10]. In a small study, Miller et al. reported a potential protective effect of NNRTI-containing therapy [19] , but in a larger study no significant differences were seen between those treated with NNRTI-containing HAART versus PI-containing HAART [9] .
Children in our study with a detectable viral load were less likely to have hypercholesterolemia than those with undetectable viral levels. This finding is biologically plausible if detectable viral load is functioning as a proxy for non-adherence to the prescribed regimen, as has been found in similar studies [1, 3, 7] . It is not clear why underweight children were found to have a greater risk of hypertriglyceridemia when other variables were controlled for in the analysis. Of interest, a high BMI was not found to be associated with hypertriglyceridemia as would be expected and has been reported in other studies of both general and HIV infected pediatric populations [1, 20, 21] . However, triglyceride results may have been impacted by the lack of mandatory fasting before the study samples were collected. We did not find children on PI þ NNRTI-containing regimens to be at greater risk of hypercholesterolemia or hypertriglyceridemia than those on PI-containing regimens; however, we did not evaluate total-HDL cholesterol ratios which have been shown to be increased in children receiving PI þ NNRTI-containing regimens [9] .
There are several limitations to our findings. First, data reported are cross sectional in nature. Thus, we have not considered the impact of ART on lipid levels over time. Rather, laboratory results were linked with the antiretrovirals the patient was taking at the time of blood collection and may in reality be affected by previous regimens. However, more than half of the participants were on their first HAART regimen and the vast majority had been on their regimen for at least 6 months at the time of lipid testing. We recognize that children on PI-containing HAART may be those with a longer history of HIV infection and ART and therefore at greater risk for hyperlipidemia, but duration of prior HAART did not differ between these two groups in our study (although those on NNRTI-containing HAART were significantly less likely to have severe HIV disease). Finally, we had hoped to include variables for race, ethnicity, and country in the analysis but were unable to due to inadequate numbers. When we limited the analysis to subjects from Brazil, Argentina and Mexico, we found that subjects from Argentina were at increased risk for hypercholesterolemia as compared to those from Brazil (AOR ¼ 3.3, 95% CI 1.6-6.8). As enrollment continues over time, this information may be available for future analyses. Though there are no data to suggest that dyslipidemia presents a threat for immediate adverse health effects in the pediatric population, the long term consequences of elevated lipid levels on the cardiovascular system are of great concern. Post-mortem examination of vascular tissue collected through the Pathobiological Determinants of Atherosclerosis in Youth and Bogalusa Heart studies revealed atherosclerotic precursors, such as fatty streaks and fibrous plaques in the arterial lining, present as early as childhood and adolescence [22, 23] . Furthermore, both studies also found a positive association between the presence of such findings and elevated serum cholesterol levels. Perhaps more alarmingly, additional evidence suggests that cardiovascular risk factors experienced during adolescence, including an elevated cholesterol level, may contribute to the development of atherosclerotic changes regardless of whether those risk factors persist in later life [24] .
In the USA, the potential impact of HAART on lipid parameters is recognized, and pediatric ART guidelines recommend regular assessment of a lipid panel [25] . However, recognition is not widespread, as the guidelines for cardiovascular risk reduction in high-risk pediatric populations do not address either HIV or ART [26] . Recognition of and concern for long term cardiovascular risks may be much less evident in resource-limited settings, especially where the capacity for frequent lab monitoring and follow up, availability of resources for diet and exercise related lifestyle modification, access to lipid-lowering agents and a variety of antiretrovirals for regimen customization are not available. Nevertheless, as WHO guidance recommends earlier initiation of life-long treatment in infants and children, the global health community works to scale up universal access to ART for HIV-infected infants and children and while the benefit of ART in saving the lives of children infected with HIV far outweighs the immediate adverse lipid effects of therapy, consideration must ultimately be given to the long-term health outcomes for children on such medications and the impact managing these effects will have on future health care providers and health systems.
